The primary purpose of this study is to evaluate the abuse potential of single oral doses of REL-1017 compared to oxycodone and placebo when administered to experienced recreational drug users. A placebo has no active drug ingredients.
A Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study to Assess the Abuse Potential of REL-1017 Relative to Oxycodone and Placebo in Healthy Experienced Recreational Drug Users
Trial Details
Study Description
Eligibility Criteria
Age
18 to 55
Gender
Both
Details
Between the ages of 18 to 55
You are a healthy experienced recreational drug user
Health Condition
Healthy Volunteer
Stipend Range
$7450 - $7450
Name of Clinical Site
Hassman Research Institute
Location
Marlton NJ
Phone
(866) 380-6565
Trial Sponsor
Hassman Research Institute
Protocol Number
REL-1017-124
Phase
1
Study Length
15 weeks
Overnight
Yes - 22 nights
Washout Period
11 days from Last Dosing Date to First Dosing
Location
30 Lake Center Executive Park, #100. Marlton, NJ 08053
Clinical Trial Site
Hassman Research Institute
30 Lake Center Executive Park, #100. Marlton, NJ 08053
Already in this trial?
Contact your clinical research site to register for trial updates
Tell your friends
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email